{"id":"NCT01988857","sponsor":"GlaxoSmithKline","briefTitle":"Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children","officialTitle":"Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix™) in Healthy Vietnamese Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-22","primaryCompletion":"2014-05-10","completion":"2014-05-10","firstPosted":"2013-11-20","resultsPosted":"2016-12-12","lastUpdate":"2018-08-02"},"enrollment":302,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Acellular Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Boostrix™","otherNames":[]}],"arms":[{"label":"dTpa Group","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and reactogenicity of GSK Biologicals' combined reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™ when given as a single injection to 6-10 year old children. Data that are available globally on the age group from four to six years of age will be used to bridge the age gap in this study and aid in the registration of the vaccine for children from the age of four years.","primaryOutcome":{"measure":"Numbers of Subjects With Any and Grade 3 Solicited Local Symptoms","timeFrame":"Within 4 days (Days 0-3) post vaccination period","effectByArm":[{"arm":"Boostrix Group","deltaMin":105,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":[],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":300},"commonTop":["Pain","Redness","Fatigue","Swelling","Headache"]}}